TY - JOUR
T1 - Respiratory syncytial virus-associated hospitalisations in Australia, 2006–2015
AU - Saravanos, Gemma L.
AU - Sheel, Meru
AU - Homaira, Nusrat
AU - Dey, Aditi
AU - Brown, Edward
AU - Wang, Han
AU - Macartney, Kristine
AU - Wood, Nicholas J.
N1 - Publisher Copyright:
© 2019 AMPCo Pty Ltd
PY - 2019/6
Y1 - 2019/6
N2 - Objective: To estimate rates of respiratory syncytial virus (RSV)-associated hospitalisation across the age spectrum, and to identify groups at particular risk of serious RSV-associated disease. Design, setting and participants: Retrospective review of National Hospital Morbidity Database data for all RSV-associated hospitalisations in Australia, 2006–2015. Main outcomes and measures: RSV-coded hospitalisation rates by age, sex, Indigenous status, jurisdiction, and seasonality (month and year); hospital length of stay; in-hospital deaths. Results: During 2006–2015, there were 63 814 hospitalisations with an RSV-specific principal diagnostic code; 60 551 (94.9%) were of children under 5 years of age. The hospitalisation rate for children under 5 years was 418 per 100 000 population; for children under 6 months of age it was 2224 per 100 000 population; the highest rate was for infants aged 0–2 months (2778 per 100 000 population). RSV-coded hospitalisation rates were higher for adults aged 65 or more than for people aged 5–64 years (incidence rate ratio [IRR], 6.6; 95% CI, 6.2–7.1), and were also higher for Indigenous Australians than other Australians (IRR, 3.3; 95% CI, 3.2–3.5). A total of 138 in-hospital deaths were recorded, including 82 of adults aged 65 years or more (59%). Conclusions: Prevention strategies targeting infants, such as maternal or early infant vaccination, would probably have the greatest impact in reducing RSV disease rates. Further characterisation of RSV disease epidemiology, particularly in older adults and Indigenous Australians, is needed to inform health care strategies.
AB - Objective: To estimate rates of respiratory syncytial virus (RSV)-associated hospitalisation across the age spectrum, and to identify groups at particular risk of serious RSV-associated disease. Design, setting and participants: Retrospective review of National Hospital Morbidity Database data for all RSV-associated hospitalisations in Australia, 2006–2015. Main outcomes and measures: RSV-coded hospitalisation rates by age, sex, Indigenous status, jurisdiction, and seasonality (month and year); hospital length of stay; in-hospital deaths. Results: During 2006–2015, there were 63 814 hospitalisations with an RSV-specific principal diagnostic code; 60 551 (94.9%) were of children under 5 years of age. The hospitalisation rate for children under 5 years was 418 per 100 000 population; for children under 6 months of age it was 2224 per 100 000 population; the highest rate was for infants aged 0–2 months (2778 per 100 000 population). RSV-coded hospitalisation rates were higher for adults aged 65 or more than for people aged 5–64 years (incidence rate ratio [IRR], 6.6; 95% CI, 6.2–7.1), and were also higher for Indigenous Australians than other Australians (IRR, 3.3; 95% CI, 3.2–3.5). A total of 138 in-hospital deaths were recorded, including 82 of adults aged 65 years or more (59%). Conclusions: Prevention strategies targeting infants, such as maternal or early infant vaccination, would probably have the greatest impact in reducing RSV disease rates. Further characterisation of RSV disease epidemiology, particularly in older adults and Indigenous Australians, is needed to inform health care strategies.
KW - Bronchial diseases
KW - Bronchitis
KW - Disease transmission, infectious
KW - Pneumonia
KW - Pneumonia, viral
KW - Prevention and control
KW - Public health
KW - Respiratory tract infections
KW - Vaccination
UR - http://www.scopus.com/inward/record.url?scp=85065425756&partnerID=8YFLogxK
U2 - 10.5694/mja2.50159
DO - 10.5694/mja2.50159
M3 - Article
SN - 0025-729X
VL - 210
SP - 447
EP - 453
JO - Medical Journal of Australia
JF - Medical Journal of Australia
IS - 10
ER -